Polymerized-type I collagen for the treatment of patients with rheumatoid arthritis. Effect of intramuscular administration in a double blind placebo-controlled clinical trial

被引:0
作者
Furuzawa-Carballeda, J.
Fenutria-Ausmequet, R.
Gil-Espinosa, V.
Lozano-Soto, F.
Teliz-Meneses, M. A.
Romero-Trejo, C.
Alcocer-Varela, J.
机构
[1] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Immunol & Rheumatol, Mexico City 14000, DF, Mexico
[2] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Radiol, Mexico City 14000, DF, Mexico
[3] Hosp Clin Barcelona, Serv Malalties Autoinmunes Sistem, Inst Clin Med Interna & Dermatol, Barcelona, Spain
[4] Hosp Clin Barcelona, Serv Immunol, Inst Invest Biomed August Pi Sunyer, IDIBAPS, Barcelona, Spain
关键词
rheumatoid arthritis; collagen-PVP; biological therapy;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To determine the efficacy, tolerance and safety of intramuscular injections of porcine type I collagen-PVP in patients with RA in a long term-therapy. Methods The study was a double blind placebo-controlled and included 30 patients with active RA (ACR). Patients were treated with intramuscular injections of 2 ml of collagen-PVP (3.4 mg of collagen) or 2 ml of placebo during 6 months. The follow up was done during the next 6 months. The primary endpoints included the Ritchie index (RI), swollen joint count, disease activity score (DAS), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). The secondary endpoints included morning stiffness, pain intensity on a visual analogue scale (VAS), and Spanish-health assessment questionnaire (HAQ-DI). Improvement was determined using American College of Rheumatology response criteria (ACR20, 50 and 70). Results Collagen-PVP was safe and well tolerated. There were no adverse events. Patients had a statistically significant improvement (p < 0.05) in collagen-PVP-treated vs. placebo at 6 months of treatment in: swollen joint count (7.1 +/- 0.8 vs. 16.0 +/- 1.6), RI (8.1 +/- 0.8 vs. 15.2 +/- 1.5), morning stiffness (9.2 +/- 3.1 vs. 29.1 +/- 5.9 min), HAQ-DI (50.0 +/- 10.8 vs. 22.9 +/- 10.3), DAS (3.0 +/- 0.2 vs. 4.9 +/- 0.3), ACR20 (78.6 vs. 71.4%), ACR50 (57.1 vs. 0%) and ACR70 (7.1 vs. 0%) and CRP (1.1 +/- 0.4 vs. 2.5 +/- 0.7). Patients treated with collagen-PVP required lower doses of methotrexate vs. placebo (12.6 +/- 0.6 vs. 14.2 +/- 0.7 at 6 months and 12.3 +/- 0.8 vs. 15.4 +/- 0.6 at 12 months; p < 0.05). Serological or haematological parameters remained unchanged. Conclusion Collagen-PVP has been shown to be a safe and well-tolerated drug for the long-term treatment of RA. Combination of collagen-PVP plus methotrexate was more efficacious than methotrexate alone. This biodrug can be useful in the treatment of RA.
引用
收藏
页码:514 / 520
页数:7
相关论文
共 32 条
[1]  
Ainola MM, 2005, CLIN EXP RHEUMATOL, V23, P644
[2]  
Arinbjarnarson S, 1997, J RHEUMATOL, V24, P269
[3]   THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[4]  
Bagchi D, 2002, INT J CLIN PHARM RES, V22, P101
[5]   Bystander suppression of murine collagen-induced arthritis by long-term nasal administration of a self type II collagen peptide [J].
Bayrak, S ;
Mitchison, NA .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1998, 113 (01) :92-95
[6]  
CARBALLEDA JF, 2003, J RHEUMATOL, V30, P140
[7]  
Cardiel MH, 2002, CLIN EXP RHEUMATOL, V20, P617
[8]  
CARDIEL MH, 1993, CLIN EXP RHEUMATOL, V11, P117
[9]  
Choy EHS, 2001, ARTHRITIS RHEUM-US, V44, P1993, DOI 10.1002/1529-0131(200109)44:9<1993::AID-ART347>3.0.CO
[10]  
2-A